

Alessandro Furlan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/719070/publications.pdf>

Version: 2024-02-01

23
papers

760
citations

759233

12
h-index

526287

27
g-index

28
all docs

28
docs citations

28
times ranked

1311
citing authors

#	ARTICLE	IF	CITATIONS
1	ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity. <i>Glycobiology</i> , 2006, 16, 54-64.	2.5	173
2	Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	83
3	Identification of new aminoacid amides containing the imidazo[2,1-b]benzothiazol-2-ylphenyl moiety as inhibitors of tumorigenesis by oncogenic Met signaling. <i>European Journal of Medicinal Chemistry</i> , 2012, 47, 239-254.	5.5	70
4	Thirty Years of Research on Met Receptor to Move a Biomarker from Bench to Bedside. <i>Cancer Research</i> , 2014, 74, 6737-6744.	0.9	64
5	Abl interconnects oncogenic Met and p53 core pathways in cancer cells. <i>Cell Death and Differentiation</i> , 2011, 18, 1608-1616.	11.2	57
6	Caspases shutdown nonsense-mediated mRNA decay during apoptosis. <i>Cell Death and Differentiation</i> , 2015, 22, 1754-1763.	11.2	41
7	Hypoxia in Solid Tumors: How Low Oxygenation Impacts the "Six Rs" of Radiotherapy. <i>Frontiers in Endocrinology</i> , 2021, 12, 742215.	3.5	38
8	"Click"™ synthesis of a triazole-based inhibitor of Met functions in cancer cells. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 4693-4696.	2.2	34
9	Ets1 triggers and orchestrates the malignant phenotype of mammary cancer cells within their matrix environment. <i>Journal of Cellular Physiology</i> , 2008, 215, 782-793.	4.1	32
10	Ets1 controls breast cancer cell balance between invasion and growth. <i>International Journal of Cancer</i> , 2014, 135, 2317-2328.	5.1	29
11	Ets-1 drives breast cancer cell angiogenic potential and interactions between breast cancer and endothelial cells. <i>International Journal of Oncology</i> , 2019, 54, 29-40.	3.3	25
12	Met acts through Abl to regulate p53 transcriptional outcomes and cell survival in the developing liver. <i>Journal of Hepatology</i> , 2012, 57, 1292-1298.	3.7	17
13	Necrosis- and apoptosis-related Met cleavages have divergent functional consequences. <i>Cell Death and Disease</i> , 2015, 6, e1769-e1769.	6.3	12
14	FRET Image Correlation Spectroscopy Reveals RNAPII-Independent P-TEFb Recruitment on Chromatin. <i>Biophysical Journal</i> , 2018, 114, 522-533.	0.5	10
15	Control of cell death/survival balance by the MET dependence receptor. <i>ELife</i> , 2020, 9, .	6.0	10
16	H3.3K27M Mutation Controls Cell Growth and Resistance to Therapies in Pediatric Glioma Cell Lines. <i>Cancers</i> , 2021, 13, 5551.	3.7	10
17	Combined Drug Action of 2-Phenylimidazo[2,1-b]Benzothiazole Derivatives on Cancer Cells According to Their Oncogenic Molecular Signatures. <i>PLoS ONE</i> , 2012, 7, e46738.	2.5	8
18	Mathematical models converge on PGC1 β as the key metabolic integrator of SIRT1 and AMPK regulation of the circadian clock. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 13171-13172.	7.1	7

#	ARTICLE	IF	CITATIONS
19	HEXIM1 Diffusion in the Nucleus Is Regulated by Its Interactions with Both 7SK and P-TEFb. <i>Biophysical Journal</i> , 2019, 117, 1615-1625.	0.5	7
20	Large-Scale Virtual Screening Against the MET Kinase Domain Identifies a New Putative Inhibitor Type. <i>Molecules</i> , 2020, 25, 938.	3.8	7
21	Evofosfamide Is Effective against Pediatric Aggressive Glioma Cell Lines in Hypoxic Conditions and Potentiates the Effect of Cytotoxic Chemotherapy and Ionizing Radiations. <i>Cancers</i> , 2021, 13, 1804.	3.7	5
22	An Overview of the Circadian Clock in the Frame of Chronotherapy: From Bench to Bedside. <i>Pharmaceutics</i> , 2022, 14, 1424.	4.5	4
23	How does met regulate the survival/apoptosis balance?. <i>Hepatology</i> , 2014, 60, 1108-1109.	7.3	2